City

Clinical trials near Monroe, United States

Active studies with a listed research site in Monroe, United States.

12active studies

6recruiting now

8countries represented

65largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 1

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Obesity, OverweightCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

United States11 locations

Novo Nordisk A/SSponsor

Updated 2026-06-25 · NCT07607587See eligibility →

Recruiting nowPhase 2

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Obesity & OverweightCondition

ERX1000, PlaceboTreatment

United States3 locations

ERX PharmaceuticalsSponsor

Updated 2026-06-22 · NCT07570758See eligibility →

Active, not recruitingPhase 2

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

ObesityCondition

Trevogrumab-Part A, Trevogrumab-Part B and Part CTreatment

Puerto Rico, United States60 locations

Regeneron PharmaceuticalsSponsor

Updated 2026-09-01 · NCT06299098See eligibility →

Active, not recruitingPhase 1, Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)Condition

ALN-4324, PlaceboTreatment

Argentina, Canada22 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-14 · NCT06845202See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

ObesityCondition

Ribupatide, PlaceboTreatment

United States35 locations

KaileraSponsor

Updated 2026-07-15 · NCT07458269See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Monroe, United States

Current studies

Related cities